Royalty Pharma PLC
NASDAQ:RPRX

Watchlist Manager
Royalty Pharma PLC Logo
Royalty Pharma PLC
NASDAQ:RPRX
Watchlist
Price: 36.12 USD 0.7% Market Closed
Market Cap: 20.3B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+380%
Revenue
Forecast
N/A
Operating Income
Forecast
-18%
Net Income
Forecast
+11%

Wall Street
Price Targets

RPRX Price Targets Summary
Royalty Pharma PLC

Wall Street analysts forecast RPRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RPRX is 41.76 USD with a low forecast of 35.02 USD and a high forecast of 53.55 USD.

RPRX Lowest Forecast
Wall Street Target
35.02 USD
3% Downside
RPRX Average Forecast
Wall Street Target
41.76 USD
16% Upside
RPRX Highest Forecast
Wall Street Target
53.55 USD
48% Upside
Lowest
Price Target
35.02 USD
3% Downside
Average
Price Target
41.76 USD
16% Upside
Highest
Price Target
53.55 USD
48% Upside
Royalty Pharma PLC Competitors:
Price Targets
GRANULES
Granules India Ltd
31% Upside
ROG
Roche Holding AG
15% Upside
CRON
Cronos Group Inc
17% Downside
069620
Daewoong Pharma
25% Upside
GRANULES
Granules India Ltd
31% Upside
ROG
Roche Holding AG
15% Upside
CRON
Cronos Group Inc
17% Downside
069620
Daewoong Pharma
25% Upside
CORT
Corcept Therapeutics Inc
96% Upside
4577
Daito Pharmaceutical Co Ltd
2% Downside
000423
Dong-E-E-Jiao Co Ltd
55% Upside

Revenue
Forecast

Revenue Estimate
Royalty Pharma PLC

For the last 6 years the compound annual growth rate for Royalty Pharma PLC's revenue is 4%. The projected CAGR for the next 3 years is 15%.

4%
Past Growth
15%
Estimated Growth
Estimates Accuracy
-16%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Royalty Pharma PLC

For the last 6 years the compound annual growth rate for Royalty Pharma PLC's operating income is -1%. The projected CAGR for the next 3 years is 32%.

-1%
Past Growth
32%
Estimated Growth
Estimates Accuracy
-31%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Royalty Pharma PLC

For the last 6 years the compound annual growth rate for Royalty Pharma PLC's net income is -8%. The projected CAGR for the next 3 years is 55%.

-8%
Past Growth
55%
Estimated Growth
Estimates Accuracy
-63%
Average Miss
What are analyst estimates?

See Also

Summary
RPRX intrinsic value, competitors valuation, and company profile.
DCF Valuation
RPRX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RPRX stock valuation using valuation multiples.
Wall Street Estimates
RPRX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RPRX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RPRX's stock price target?
Price Target
41.76 USD

According to Wall Street analysts, the average 1-year price target for RPRX is 41.76 USD with a low forecast of 35.02 USD and a high forecast of 53.55 USD.

What is Royalty Pharma PLC's Revenue forecast?
Projected CAGR
15%

For the last 6 years the compound annual growth rate for Royalty Pharma PLC's revenue is 4%. The projected CAGR for the next 3 years is 15%.

What is Royalty Pharma PLC's Operating Income forecast?
Projected CAGR
32%

For the last 6 years the compound annual growth rate for Royalty Pharma PLC's operating income is -1%. The projected CAGR for the next 3 years is 32%.

What is Royalty Pharma PLC's Net Income forecast?
Projected CAGR
55%

For the last 6 years the compound annual growth rate for Royalty Pharma PLC's net income is -8%. The projected CAGR for the next 3 years is 55%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 266,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.